| Trial ID: | L2567 |
| Source ID: | NCT03962010
|
| Associated Drug: |
Gx-G6
|
| Title: |
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: GX-G6|DRUG: Control
|
| Outcome Measures: |
Primary: Change in HbA1c, Week 12 |
|
| Sponsor/Collaborators: |
Sponsor: Genexine, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
78
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-06-01
|
| Completion Date: |
2022-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2019-05-23
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT03962010
|
